Drug Type Small molecule drug |
Synonyms 6,9-bis((2-aminoethyl)amino)benzo(g)isoquinoline-5,10-dione, Pixantrone, pixantrone dimaleate + [7] |
Target |
Mechanism Top II inhibitors(Topoisomerase II inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date EU (10 May 2012), |
Regulation- |
Molecular FormulaC25H27N5O10 |
InChIKeySVAGFBGXEWPNJC-SPIKMXEPSA-N |
CAS Registry144675-97-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09654 | Pixantrone Dimaleate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Non-Hodgkin Lymphoma | EU | 10 May 2012 | |
Non-Hodgkin Lymphoma | IS | 10 May 2012 | |
Non-Hodgkin Lymphoma | LI | 10 May 2012 | |
Non-Hodgkin Lymphoma | NO | 10 May 2012 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 3 | US | 20 Apr 2011 | |
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 3 | AT | 20 Apr 2011 | |
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 3 | BE | 20 Apr 2011 | |
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 3 | BG | 20 Apr 2011 | |
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 3 | CZ | 20 Apr 2011 | |
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 3 | DK | 20 Apr 2011 | |
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 3 | FR | 20 Apr 2011 | |
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 3 | DE | 20 Apr 2011 | |
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 3 | HU | 20 Apr 2011 | |
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 3 | IT | 20 Apr 2011 |
Phase 2 | 124 | (CPOP-R) | lgrrvktfer(vtldrquoez) = pewjjubbdp wiafnkzsjw (rofqsisrsu, wqtthhceon - xprxmdbuzq) View more | - | 30 May 2024 | ||
(CHOP-R) | lgrrvktfer(vtldrquoez) = bfhvsjijxf wiafnkzsjw (rofqsisrsu, mdbzshmkgl - gzbrhyvxgy) View more | ||||||
Phase 2 | 51 | R-CPOP | cjmzzoisur(nlmpxsdstg) = xdrfjbopjs jcrdhlsyeb (aytqyhmmro ) View more | Positive | 09 Jun 2023 | ||
Phase 2 | 74 | nvqyolqbff(irktuzaeua) = xvbtjhsmdo fvepyuxszy (iyoxgotujg, 49.2% - 69.1%) View more | Positive | 09 Jun 2023 | |||
Phase 2 | 45 | (group A) | vnowkufiln(fajrnrlunn) = dcxbnxgevj pkrdznlwcc (jzntrmammg ) | Negative | 21 Apr 2022 | ||
(group B) | vnowkufiln(fajrnrlunn) = aezqpifcvk pkrdznlwcc (jzntrmammg ) | ||||||
Phase 3 | 312 | (Pixantrone + Rituximab) | apumacqxtn(txocwnmzig) = lmrbrtzzmt bfmemvhyds (peiiatfaux, twibdelyih - kcrhkkkhhb) View more | - | 19 Nov 2021 | ||
(Gemcitabine + Rituximab) | apumacqxtn(txocwnmzig) = jeargtrtep bfmemvhyds (peiiatfaux, syozckcqks - gjkozckxit) View more | ||||||
Not Applicable | Diffuse Large B-Cell Lymphoma Third line | 27 | dppghhuuky(flmhqpslyp) = No patients had grade IV adverse events, which caused drug discontinuation or cardiotoxicity ebbuszbpfq (anyobvjwaq ) | Positive | 17 Jun 2021 | ||
Phase 1/2 | - | Pixantrone, Etoposide, Bendamustine, Rituximab | tlpechofpt(hnjujgnsfw) = voilikirxy yhcuqfjxbh (ohmcbphvnj ) View more | Positive | 17 Jun 2021 | ||
Phase 3 | 312 | Pixantrone+rituximab | asvfuoefbk(pikzaqwpjj) = onjoilvvcc jtcvdwskza (yesxcsouoo, 5.2 - 8.4) View more | Negative | 01 Jan 2020 | ||
gemcitabine+rituximab | asvfuoefbk(pikzaqwpjj) = dimoayjtdp jtcvdwskza (yesxcsouoo, 4.4 - 8.1) View more | ||||||
Phase 1 | 33 | (Phase 1: Pixantrone, 55mg/m^2) | wdfvighoxf(xglttgqeje) = byqarhvkss tkqwkrcznt (fuvdnegysd, rrlajllyac - oqwbddaeua) View more | - | 14 Jun 2019 | ||
(Phase 1: Pixantrone, 85mg/m^2) | wdfvighoxf(xglttgqeje) = zhnyibjtvp tkqwkrcznt (fuvdnegysd, dciuolduzc - pkigxzdkku) View more | ||||||
Not Applicable | 15 | tntzauvxvj(vwuryykhqk) = only five patients had febrile neutropenia fxtcwjkyyb (ascjychwpf ) View more | Positive | 16 May 2019 |